English (United States)
English (United States)
IsiZulu (Ningizimu Afrika)
Nederlands (Nederland)
Português (Portugal)

Lesi isifundo sesigaba sesi-3, esingahleliwe, esilawulwa yi-placebo sokusebenza nokuphepha kwe-enlicitide decanoate, i-oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, kubahlanganyeli abasengozini enkulu yenhliziyo nemithambo yegazi. Inhloso eyinhloko ukuhlola ukusebenza kahle kwe-enlicitide decanoate uma kuqhathaniswa ne-placebo ekwandiseni isikhathi sokuvela kokuqala kwezehlakalo ezimbi kakhulu zenhliziyo nemithambo yegazi (MACE) okuhlanganisa ukufa kwe-coronary heart disease (CHD), ischemic stroke, myocardial infarction (MI), i-acute limb ischemia noma ukunqunywa okukhulu kwemithambo, noma ukuvuselelwa kabusha kwemithambo ephuthumayo.

I-NCT06008756

2022-502781-24-00

 Icon

All ages

 Icon

KONKE

Trial phase Icon
Trial start Icon
  • Okthoba 9, 2023
  • Novemba 29, 2029
  • Novemba 29, 2029

I-NCT06008756

2022-502781-24-00

This site is registered on wpml.org as a development site. Switch to a production site key to remove this banner.